Human Genome's Resistance To $2.6B GSK Offer Draws Fire
Plaintiffs in a putative class action filed last month in Montgomery County court are now seeking a temporary restraining order that would kill a poison pill meant to deter GSK's advances.
Human Genome, which makes gene-targeting medicines, rejected GSK's offer in April as too low and on May 17 launched a shareholder-rights plan to...
Already a subscriber? Click here to login